Observational Study on Treatment Outcomes for Patients with Relapsed or Refractory Acute Myeloid Leukemia RR AML in Europe

What this Trial Is About

Researchers are conducting an observational, prospective cohort study to collect data from patients diagnosed with relapsed or refractory acute myeloid leukemia RR AML. This hard-to-treat condition has a poor survival rate despite advances in intensive treatments. The study aims to gather real-world data on outcomes and the effectiveness of new therapies, including in diverse populations such as children, elderly, and those with rare mutations across Europe. Participants will be registered into the STREAM platform where baseline and follow-up data will be recorded according to their normal clinical care. Patients will be followed for up to 4 years, with no experimental treatments assigned by the study. The study facilitates data collection across multiple sites using a GDPR-compliant system to allow cross-country participation and to support future international trials. Participants will provide informed consent and their clinical information, diagnosis methods, treatment options, and outcomes will be monitored. Researchers will measure overall survival, remission rates, event-free survival, relapse-free survival, transplant rates, and associations between clinical and biological factors over 8 years. This study supports understanding RR AML in routine practice and helps identify populations for future research.

Master Framework For Relapse or Refractory Acute Myeloid Leukemia